N-(4-chlorophenyl)-1-methyl-9-(1-methylpyrazol-4-yl)-6,7-dihydro-5H-triazolo[5,1-a][2]benzazepin-7-amine
C22H21ClN6 — CID 155042790
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-(4-chlorophenyl)-1-methyl-9-(1-methylpyrazol-4-yl)-6,7-dihydro-5H-triazolo[5,1-a][2]benzazepin-7-amine
N-(4-chlorophenyl)-1-methyl-9-(1-methylpyrazol-4-yl)-6,7-dihydro-5H-triazolo[5,1-a][2]benzazepin-7-amine (PubChem CID 155042790) has the molecular formula C22H21ClN6 and a molecular weight of 404.91 g/mol. Its IUPAC name is N-(4-chlorophenyl)-1-methyl-9-(1-methylpyrazol-4-yl)-6,7-dihydro-5H-triazolo[5,1-a][2]benzazepin-7-amine.
Molecular Properties
| Compound Name | N-(4-chlorophenyl)-1-methyl-9-(1-methylpyrazol-4-yl)-6,7-dihydro-5H-triazolo[5,1-a][2]benzazepin-7-amine |
|---|---|
| PubChem CID | 155042790 |
| Molecular Formula | C22H21ClN6 |
| Molecular Weight | 404.91 g/mol |
| Exact Mass | 404.15 |
| IUPAC Name | N-(4-chlorophenyl)-1-methyl-9-(1-methylpyrazol-4-yl)-6,7-dihydro-5H-triazolo[5,1-a][2]benzazepin-7-amine |
| SMILES | Cc1nnn2c1-c1ccc(-c3cnn(C)c3)cc1C(Nc1ccc(Cl)cc1)CC2 |
| InChI | InChI=1S/C22H21ClN6/c1-14-22-19-8-3-15(16-12-24-28(2)13-16)11-20(19)21(9-10-29(22)27-26-14)25-18-6-4-17(23)5-7-18/h3-8,11-13,21,25H,9-10H2,1-2H3 |
| InChIKey | DPRCEMFMSVGGGK-UHFFFAOYSA-N |
| XLogP | 4.86 |
| TPSA | 60.56 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 3 |
| Heavy Atoms | 29 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 404.91 |
| LogP ≤ 5 | 4.86 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 155042790 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.